Amgen Inc. (NASDAQ: AMGN, SEHK: 4332) is an international biotechnology company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotech firm. The company employs approximately 17,000 staff members. Its products include Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara, Nplate, and Prolia. Epogen and Neupogen (the company's first products on the market) were the two most successful biopharmaceutical products at the time of their respective releases.
BusinessWeek ranked Amgen first on the S&P 500 for being one of the most "future-oriented" of those five hundred corporations.[2] BusinessWeek ostensibly calculated the ratio of research and development spending, combined with capital spending, to total outlays; Amgen had the fourth highest ratio, at 506:1000.
Amgen is the largest employer in Thousand Oaks and second only to the United States Navy in terms of number of people employed in Ventura County.
With plans to expand into a new campus under construction in South San Francisco, Amgen abruptly halted construction on the plans and instead put the 365,000 square feet (33,900 m2) of new space on the sublease market.[3]
It is a leading member of the U.S. Global Leadership Coalition, a coalition of over 400 companies and NGOs that promotes increased funding for US diplomatic and international development programs.[4]
In 2006, Amgen began sponsoring the Tour of California, one of only three major Union Cycliste Internationale events in the United States.
Amgen Inc. (Amgen), incorporated in 1980, is an independent biotechnology medicines company. Amgen discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology. As of December 31, 2010, the Company marketed primarily recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. Its principal products are Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoiesis-stimulating agents (ESAs) that stimulate the production of red blood cells; Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony stimulating factor (G-CSF), both of which selectively stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection), and Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body’s response to inflammatory diseases. In March 2011, the Company acquired BioVex Group, Inc.
During the year ended December 31, 2010, Amgen’s principal products represented 91% of its revenues. Amgen maintain sales and marketing forces primarily in the United States, Europe and Canada. Together with the Company’s partners, it markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies. In addition to the Company’s marketed products, it has various product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular and general medicine, which includes neurology. Amgen operates commercial and/or clinical manufacturing facilities in the United States, Puerto Rico and the Netherlands. The Company markets its principal products, Aranesp, EPOGEN, Neulasta, NEUPOGEN and ENBREL in supportive cancer care, nephrology and inflammation.
Aranesp (darbepoetin alfa)
Aranesp is a protein that stimulates red blood cell production. The Company has a license granted by Kirin-Amgen, Inc. (KA), a joint venture between Kirin Holdings Company, Limited (Kirin) and Amgen, to manufacture and market Aranesp in the United States, all European countries, Canada, Australia, New Zealand, Mexico, all Central and South American countries and certain countries in Central Asia, Africa and the Middle East. Amgen markets Aranesp primarily in the United States and Europe, for the treatment of anemia associated with chronic renal failure (CRF) (both in patients on dialysis and patients not on dialysis) and is also indicated for the treatment of anemia due to concomitant chemotherapy in patients with non-myeloid malignancies.
EPOGEN (Epoetin alfa)
EPOGEN is a protein that stimulates red blood cell production. On February 16, 2010, Amgen and Centocor Ortho Biotech Products, L.P. (Centocor Ortho Biotech Products), a subsidiary of Johnson & Johnson (J&J), announced that the United States Food and Drug Administration (FDA) approved a risk evaluation and mitigation strategy (REMS) for ESAs, which includes Aranesp, EPOGEN and Procrit (Epoetin alfa). It has a license to manufacture and market recombinant human erythropoietin in the United States under a licensing agreement with KA. The Company markets EPOGEN in the United States for the treatment of anemic adult and pediatric patients with CRF who are on dialysis. EPOGEN is indicated for elevating or maintaining the red blood cell level (as determined by hematocrit (Hb) measurements) and decreasing the need for blood transfusions in these patients.
Neulasta (pegfilgrastim)/NEUPOGEN (Filgrastim)
Neulasta and NEUPOGEN stimulate production of certain white blood cells known as neutrophils. Amgen has a license to manufacture and market Neulasta and NEUPOGEN in the United States, Europe, Canada, Australia and New Zealand under a licensing agreement with KA. It markets Neulasta and NEUPOGEN primarily in the United States and Europe. NEUPOGEN is used as brand name for Filgrastim, its recombinant-methionyl human G-CSF. Neulasta is used as brand name for pegfilgrastim, a pegylated protein based on the Filgrastim molecule. Neulasta and NEUPOGEN are prescribed more frequently in the curative setting, in which myelosuppressive chemotherapy is administered with the intent to cure cancer, rather than in the palliative setting, in which myelosuppressive chemotherapy is administered to treat other complications of cancer by managing tumor growth. The Company markets Neulasta and NEUPOGEN primarily in the United States and Europe. Filgrastim is also marketed under the brand name GRANULOKINE in Italy.
Enbrel (etanercept)
ENBREL is Amgen’s brand name for its TNF receptor fusion protein that inhibits the binding to TNF receptors, which can result in a significant reduction in inflammatory activity. As of December 31, 2010, in addition, ENBREL was indicated for the treatment of adult patients with the conditions, including moderately to severely active RA, chronic moderate to severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy, active psoriatic arthritis, and active ankylosing spondylitis. ENBREL is also approved for the treatment of moderately to severely active polyarticular juvenile idopathic arthritis in patients ages two and older. It markets ENBREL under a collaboration agreement with Pfizer Inc. (Pfizer) in the United States and Canada.
Other
The Company’s other marketed products consisted of Sensipar/Mimpara (cinacalcet), Vectibix (panitumumab), Nplate (romiplostim), Prolia (denosumab) and XGEVA (denosumab). Sensipar is its brand name in the United States and Mimpara is its brand name emark in Europe, for cinacalcet, its small molecule medicine used in treating chronic kidney disease (CKD) patients on dialysis who produce too much parathyroid hormone (PTH), a condition known as secondary hyperparathyroidism. Amgen markets Sensipar/Mimpara primarily in the United States and Europe. Vectibix is the Company’s brand name for panitumumab, its monoclonal antibody for the treatment of patients with EGFr expressing metastatic colorectal cancer (mCRC) after disease progression on, or following fluoropyrimidine, oxaliplatin and irinotecan containing chemotherapy regimens.
The Company’s Nplate is a platelet producer, approved by FDA for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic immune thrombocytopenic purpura (ITP). Nplate works by raising and sustaining platelet counts. Amgen has a license by KA to manufacture and market Nplate in the United States, all European countries, Canada, Australia, New Zealand, Mexico, all Central and South American countries and certain countries in Central Asia, Africa and the Middle East. During 2010, it had approved REMS for Nplate, which included a medication guide, a healthcare provider communication plan and certain elements to assure safe use (including restricted distribution, registry, healthcare provider, institution and patient enrollment).
During 2010, Amgen launched Prolia and XGEVA, both of which contained the same active ingredient, but which were approved for different indications, patient populations, doses and frequencies of administration. On June 1, 2010, the FDA approved Prolia for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. On November 18, 2010, the FDA approved XGEVA for the prevention of skeletal related events (SREs) in patients with bone metastases from solid tumors. XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma. On December 12, 2010, the Company announced top-line results from a phase III trial evaluating XGEVA versus placebo in men with castrate-resistant prostate cancer.
The Company competes with Centocor Ortho Biotech Products, Janssen-Cilag, F. Hoffmann-La Roche Ltd., Hospira Inc, Stada Arzneimittel AG, Sandoz GmbH, Hexal Biotech Forschungs GmbH, Medice Arzneimittel Putter GmbH & Company KG, CT Arztneimittel GmbH, Bayer HealthCare Pharmaceuticals, Chugai Pharmaceuticals Co., Ltd., Sanofi-Aventis, Ratiopharm GmbH, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Merck KGaA, Genzyme Corporation, Abbott Laboratories, Roxane Laboratories, Fresenius Medical Care AG & Co. KGaA, Shire Pharmaceuticals Group Plc, Centocor Ortho Biotech Inc., Duramed Pharmaceuticals, Inc., Centocor Ortho Biotech, Nektar Therapeutics, DAVA Pharmaceuticals, Inc., Biogen IDEC Inc., and Novartis AG.
The launch of Infergen in October 1997 set Amgen on track toward achieving its goal of releasing five new products in five years. The company filed and received license applications for Stemgen, a drug that generated the growth of stem cells and led to a faster recovery of blood cells after chemotherapy, and made clinical trial progress on MGDF, KGF, leptin, and NESP. It also in-licensed the worldwide rights to Guilford Pharmaceuticals' FKBP-neuroimunophilins, oral compounds that showed signs of treating neurodegenerative disorders, including Parkinson's and Alzheimer's. Yet despite Amgen's laboratory successes, the year was one of mixed financial results. A significant change in the government's Medicare reimbursement policy led to an unanticipated reduction in the rate of growth for Epogen, which nonetheless brought in $1.1 billion. Worldwide Neupogen sales at $1 billion were also negatively affected by the strengthening of the U.S. dollar, the continued tightening of healthcare budgets in some European countries, and the improved antiviral therapies that reduced the incidence of depleted white blood cell levels in AIDS patients. In 1998 Amgen received further bad news when it was discovered that the standard dose of Epogen could be reduced by a third if injected under the skin rather than being administered intravenously. Far more tragic, though, was the news that a high number of deaths were reported among heart patients who used Epogen.
Still Amgen continued to build upon its foundation in 1998 and 1999. Research and development efforts were driven by internal research, in-licensing, and selective acquisition activities. In 1999 it invested in Abarelix, developed by Praecis Pharmaceuticals to reduce testosterone levels as part of treating prostate cancer. It also applied for FDA approval for an experimental drug to treat rheumatoid arthritis. During this time, Amgen shares rocketed 140 percent by the first quarter of 1999. With sales of its hallmark drugs Epogen and Neupogen, as well as Intergen still rising, and first quarter 1999 earnings up 32 percent, Amgen was prepared to enter the next century as the biggest biotechnology company in the world.
Principal Subsidiaries: Amgen Australia Pty Ltd.; Amgen N.V.; Amgen Canada Inc.; Amgen Greater China Ltd.; Amgen GmbH (Germany); Amgen S.A. (France); Amgen S.p.A. (Italy); Amgen K.K. (Japan); Amgen B.V. (Netherlands); Amgen-Biofarmaceutica (Portugal); Amgen S.A. (Spain); Amgen (Europe) AG (Switzerland); Kirin-Amgen, Inc. (Switzerland); Amgen Limited (U.K.); Amgen Sales Corporation (West Indies).
OVERALL
Beta: 0.47
Market Cap (Mil.): $53,044.05
Shares Outstanding (Mil.): 933.05
Annual Dividend: --
Yield (%): --
FINANCIALS
AMGN.O Industry Sector
P/E (TTM): 11.83 25.11 38.20
EPS (TTM): 2.16 -- --
ROI: 12.69 -1.78 1.91
ROE: 19.38 -1.25 2.51
Statistics:
Public Company
Incorporated: 1980
Employees: 1,700
Sales: $2.71 billion (1998)
Stock Exchanges: NASDAQ
Ticker Symbol: AMGN
NAIC: 325412 Pharmaceutical Preparation Manufacturing
Name Age Since Current Position
Sharer, Kevin 63 2010 Chairman of the Board, Chief Executive Officer
Bradway, Robert 48 2010 President, Chief Operating Officer
Peacock, Jonathan 52 2010 Chief Financial Officer, Executive Vice President
Bonanni, Fabrizio 64 2007 Executive Vice President - Operations
Perlmutter, Roger 58 2001 Executive Vice President - Research & Development
Richo, Anna 50 2008 Senior Vice President, Chief Compliance Officer
Scott, David 58 2004 Senior Vice President, General Counsel, Secretary
McNamee, Brian 54 2001 Senior Vice President - Human Resources
Beier, David 62 2008 Senior Vice President - Global Government and Corporate Affairs
Pelham, Judith 65 1995 Independent Director
Gluck, Frederick 75 1998 Independent Director
Choate, Jerry 72 1998 Independent Director
Omenn, Gilbert 69 1987 Independent Director
Baltimore, David 73 1999 Independent Director
Reason, J. Paul 70 2001 Independent Director
Biondi, Frank 66 2002 Independent Director
Schaeffer, Leonard 65 2004 Independent Director
Herringer, Frank 68 2004 Independent Director
Coffman, Vance 67 2007 Independent Director
de Carbonnel, Francois 65 2008 Independent Director
Henderson, Rebecca 50 2009 Independent Director
Sugar, Ronald 62 2010 Independent Director
Address:
Amgen Center
1840 Dehavilland Drive
Thousand Oaks, California 91320-1789
U.S.A.
BusinessWeek ranked Amgen first on the S&P 500 for being one of the most "future-oriented" of those five hundred corporations.[2] BusinessWeek ostensibly calculated the ratio of research and development spending, combined with capital spending, to total outlays; Amgen had the fourth highest ratio, at 506:1000.
Amgen is the largest employer in Thousand Oaks and second only to the United States Navy in terms of number of people employed in Ventura County.
With plans to expand into a new campus under construction in South San Francisco, Amgen abruptly halted construction on the plans and instead put the 365,000 square feet (33,900 m2) of new space on the sublease market.[3]
It is a leading member of the U.S. Global Leadership Coalition, a coalition of over 400 companies and NGOs that promotes increased funding for US diplomatic and international development programs.[4]
In 2006, Amgen began sponsoring the Tour of California, one of only three major Union Cycliste Internationale events in the United States.
Amgen Inc. (Amgen), incorporated in 1980, is an independent biotechnology medicines company. Amgen discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology. As of December 31, 2010, the Company marketed primarily recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. Its principal products are Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoiesis-stimulating agents (ESAs) that stimulate the production of red blood cells; Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony stimulating factor (G-CSF), both of which selectively stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection), and Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body’s response to inflammatory diseases. In March 2011, the Company acquired BioVex Group, Inc.
During the year ended December 31, 2010, Amgen’s principal products represented 91% of its revenues. Amgen maintain sales and marketing forces primarily in the United States, Europe and Canada. Together with the Company’s partners, it markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies. In addition to the Company’s marketed products, it has various product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular and general medicine, which includes neurology. Amgen operates commercial and/or clinical manufacturing facilities in the United States, Puerto Rico and the Netherlands. The Company markets its principal products, Aranesp, EPOGEN, Neulasta, NEUPOGEN and ENBREL in supportive cancer care, nephrology and inflammation.
Aranesp (darbepoetin alfa)
Aranesp is a protein that stimulates red blood cell production. The Company has a license granted by Kirin-Amgen, Inc. (KA), a joint venture between Kirin Holdings Company, Limited (Kirin) and Amgen, to manufacture and market Aranesp in the United States, all European countries, Canada, Australia, New Zealand, Mexico, all Central and South American countries and certain countries in Central Asia, Africa and the Middle East. Amgen markets Aranesp primarily in the United States and Europe, for the treatment of anemia associated with chronic renal failure (CRF) (both in patients on dialysis and patients not on dialysis) and is also indicated for the treatment of anemia due to concomitant chemotherapy in patients with non-myeloid malignancies.
EPOGEN (Epoetin alfa)
EPOGEN is a protein that stimulates red blood cell production. On February 16, 2010, Amgen and Centocor Ortho Biotech Products, L.P. (Centocor Ortho Biotech Products), a subsidiary of Johnson & Johnson (J&J), announced that the United States Food and Drug Administration (FDA) approved a risk evaluation and mitigation strategy (REMS) for ESAs, which includes Aranesp, EPOGEN and Procrit (Epoetin alfa). It has a license to manufacture and market recombinant human erythropoietin in the United States under a licensing agreement with KA. The Company markets EPOGEN in the United States for the treatment of anemic adult and pediatric patients with CRF who are on dialysis. EPOGEN is indicated for elevating or maintaining the red blood cell level (as determined by hematocrit (Hb) measurements) and decreasing the need for blood transfusions in these patients.
Neulasta (pegfilgrastim)/NEUPOGEN (Filgrastim)
Neulasta and NEUPOGEN stimulate production of certain white blood cells known as neutrophils. Amgen has a license to manufacture and market Neulasta and NEUPOGEN in the United States, Europe, Canada, Australia and New Zealand under a licensing agreement with KA. It markets Neulasta and NEUPOGEN primarily in the United States and Europe. NEUPOGEN is used as brand name for Filgrastim, its recombinant-methionyl human G-CSF. Neulasta is used as brand name for pegfilgrastim, a pegylated protein based on the Filgrastim molecule. Neulasta and NEUPOGEN are prescribed more frequently in the curative setting, in which myelosuppressive chemotherapy is administered with the intent to cure cancer, rather than in the palliative setting, in which myelosuppressive chemotherapy is administered to treat other complications of cancer by managing tumor growth. The Company markets Neulasta and NEUPOGEN primarily in the United States and Europe. Filgrastim is also marketed under the brand name GRANULOKINE in Italy.
Enbrel (etanercept)
ENBREL is Amgen’s brand name for its TNF receptor fusion protein that inhibits the binding to TNF receptors, which can result in a significant reduction in inflammatory activity. As of December 31, 2010, in addition, ENBREL was indicated for the treatment of adult patients with the conditions, including moderately to severely active RA, chronic moderate to severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy, active psoriatic arthritis, and active ankylosing spondylitis. ENBREL is also approved for the treatment of moderately to severely active polyarticular juvenile idopathic arthritis in patients ages two and older. It markets ENBREL under a collaboration agreement with Pfizer Inc. (Pfizer) in the United States and Canada.
Other
The Company’s other marketed products consisted of Sensipar/Mimpara (cinacalcet), Vectibix (panitumumab), Nplate (romiplostim), Prolia (denosumab) and XGEVA (denosumab). Sensipar is its brand name in the United States and Mimpara is its brand name emark in Europe, for cinacalcet, its small molecule medicine used in treating chronic kidney disease (CKD) patients on dialysis who produce too much parathyroid hormone (PTH), a condition known as secondary hyperparathyroidism. Amgen markets Sensipar/Mimpara primarily in the United States and Europe. Vectibix is the Company’s brand name for panitumumab, its monoclonal antibody for the treatment of patients with EGFr expressing metastatic colorectal cancer (mCRC) after disease progression on, or following fluoropyrimidine, oxaliplatin and irinotecan containing chemotherapy regimens.
The Company’s Nplate is a platelet producer, approved by FDA for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic immune thrombocytopenic purpura (ITP). Nplate works by raising and sustaining platelet counts. Amgen has a license by KA to manufacture and market Nplate in the United States, all European countries, Canada, Australia, New Zealand, Mexico, all Central and South American countries and certain countries in Central Asia, Africa and the Middle East. During 2010, it had approved REMS for Nplate, which included a medication guide, a healthcare provider communication plan and certain elements to assure safe use (including restricted distribution, registry, healthcare provider, institution and patient enrollment).
During 2010, Amgen launched Prolia and XGEVA, both of which contained the same active ingredient, but which were approved for different indications, patient populations, doses and frequencies of administration. On June 1, 2010, the FDA approved Prolia for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. On November 18, 2010, the FDA approved XGEVA for the prevention of skeletal related events (SREs) in patients with bone metastases from solid tumors. XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma. On December 12, 2010, the Company announced top-line results from a phase III trial evaluating XGEVA versus placebo in men with castrate-resistant prostate cancer.
The Company competes with Centocor Ortho Biotech Products, Janssen-Cilag, F. Hoffmann-La Roche Ltd., Hospira Inc, Stada Arzneimittel AG, Sandoz GmbH, Hexal Biotech Forschungs GmbH, Medice Arzneimittel Putter GmbH & Company KG, CT Arztneimittel GmbH, Bayer HealthCare Pharmaceuticals, Chugai Pharmaceuticals Co., Ltd., Sanofi-Aventis, Ratiopharm GmbH, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Merck KGaA, Genzyme Corporation, Abbott Laboratories, Roxane Laboratories, Fresenius Medical Care AG & Co. KGaA, Shire Pharmaceuticals Group Plc, Centocor Ortho Biotech Inc., Duramed Pharmaceuticals, Inc., Centocor Ortho Biotech, Nektar Therapeutics, DAVA Pharmaceuticals, Inc., Biogen IDEC Inc., and Novartis AG.
The launch of Infergen in October 1997 set Amgen on track toward achieving its goal of releasing five new products in five years. The company filed and received license applications for Stemgen, a drug that generated the growth of stem cells and led to a faster recovery of blood cells after chemotherapy, and made clinical trial progress on MGDF, KGF, leptin, and NESP. It also in-licensed the worldwide rights to Guilford Pharmaceuticals' FKBP-neuroimunophilins, oral compounds that showed signs of treating neurodegenerative disorders, including Parkinson's and Alzheimer's. Yet despite Amgen's laboratory successes, the year was one of mixed financial results. A significant change in the government's Medicare reimbursement policy led to an unanticipated reduction in the rate of growth for Epogen, which nonetheless brought in $1.1 billion. Worldwide Neupogen sales at $1 billion were also negatively affected by the strengthening of the U.S. dollar, the continued tightening of healthcare budgets in some European countries, and the improved antiviral therapies that reduced the incidence of depleted white blood cell levels in AIDS patients. In 1998 Amgen received further bad news when it was discovered that the standard dose of Epogen could be reduced by a third if injected under the skin rather than being administered intravenously. Far more tragic, though, was the news that a high number of deaths were reported among heart patients who used Epogen.
Still Amgen continued to build upon its foundation in 1998 and 1999. Research and development efforts were driven by internal research, in-licensing, and selective acquisition activities. In 1999 it invested in Abarelix, developed by Praecis Pharmaceuticals to reduce testosterone levels as part of treating prostate cancer. It also applied for FDA approval for an experimental drug to treat rheumatoid arthritis. During this time, Amgen shares rocketed 140 percent by the first quarter of 1999. With sales of its hallmark drugs Epogen and Neupogen, as well as Intergen still rising, and first quarter 1999 earnings up 32 percent, Amgen was prepared to enter the next century as the biggest biotechnology company in the world.
Principal Subsidiaries: Amgen Australia Pty Ltd.; Amgen N.V.; Amgen Canada Inc.; Amgen Greater China Ltd.; Amgen GmbH (Germany); Amgen S.A. (France); Amgen S.p.A. (Italy); Amgen K.K. (Japan); Amgen B.V. (Netherlands); Amgen-Biofarmaceutica (Portugal); Amgen S.A. (Spain); Amgen (Europe) AG (Switzerland); Kirin-Amgen, Inc. (Switzerland); Amgen Limited (U.K.); Amgen Sales Corporation (West Indies).
OVERALL
Beta: 0.47
Market Cap (Mil.): $53,044.05
Shares Outstanding (Mil.): 933.05
Annual Dividend: --
Yield (%): --
FINANCIALS
AMGN.O Industry Sector
P/E (TTM): 11.83 25.11 38.20
EPS (TTM): 2.16 -- --
ROI: 12.69 -1.78 1.91
ROE: 19.38 -1.25 2.51
Statistics:
Public Company
Incorporated: 1980
Employees: 1,700
Sales: $2.71 billion (1998)
Stock Exchanges: NASDAQ
Ticker Symbol: AMGN
NAIC: 325412 Pharmaceutical Preparation Manufacturing
Name Age Since Current Position
Sharer, Kevin 63 2010 Chairman of the Board, Chief Executive Officer
Bradway, Robert 48 2010 President, Chief Operating Officer
Peacock, Jonathan 52 2010 Chief Financial Officer, Executive Vice President
Bonanni, Fabrizio 64 2007 Executive Vice President - Operations
Perlmutter, Roger 58 2001 Executive Vice President - Research & Development
Richo, Anna 50 2008 Senior Vice President, Chief Compliance Officer
Scott, David 58 2004 Senior Vice President, General Counsel, Secretary
McNamee, Brian 54 2001 Senior Vice President - Human Resources
Beier, David 62 2008 Senior Vice President - Global Government and Corporate Affairs
Pelham, Judith 65 1995 Independent Director
Gluck, Frederick 75 1998 Independent Director
Choate, Jerry 72 1998 Independent Director
Omenn, Gilbert 69 1987 Independent Director
Baltimore, David 73 1999 Independent Director
Reason, J. Paul 70 2001 Independent Director
Biondi, Frank 66 2002 Independent Director
Schaeffer, Leonard 65 2004 Independent Director
Herringer, Frank 68 2004 Independent Director
Coffman, Vance 67 2007 Independent Director
de Carbonnel, Francois 65 2008 Independent Director
Henderson, Rebecca 50 2009 Independent Director
Sugar, Ronald 62 2010 Independent Director
Address:
Amgen Center
1840 Dehavilland Drive
Thousand Oaks, California 91320-1789
U.S.A.